Barclays Reiterates “€82.00” Price Target for Merck KGaA (MRK)

Barclays set a €82.00 ($95.35) price target on Merck KGaA (FRA:MRK) in a report issued on Friday, Borsen Zeitung reports. The brokerage currently has a sell rating on the healthcare company’s stock.

Several other research analysts also recently commented on the stock. UBS Group set a €104.00 ($120.93) price target on shares of Merck KGaA and gave the stock a neutral rating in a research note on Thursday, April 25th. Independent Research set a €103.00 ($119.77) price target on shares of Merck KGaA and gave the stock a neutral rating in a research note on Tuesday, April 16th. DZ Bank reaffirmed a neutral rating on shares of Merck KGaA in a research note on Tuesday, April 16th. Sanford C. Bernstein set a €108.00 ($125.58) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Monday, April 15th. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a neutral rating in a report on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have given a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of €100.95 ($117.38).

MRK stock opened at €96.78 ($112.53) on Friday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: Trading Stocks – What are percentage gainers?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.